Pharmacological evidence of bradykinin regeneration from extended sequences that behave as peptidase-activated B2 receptor agonists

Frontiers in Pharmacology

Volumn 5 MAR, Issue , 2014, Pages

  Charest Morin, Xavier ^a   Roy, Caroline ^a   Fortin, Émile Jacques ^a   Bouthillier, Johanne ^a   Marceau, François ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Angiotensin converting enzyme; Arginine carboxypeptidases; Bradykinin; Vascular smooth muscle

Indexed keywords

ARGININE CARBOXYPEPTIDASE; BRADYKININ; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR AGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL PEPTIDASE IV; ENALAPRILAT; GREEN FLUORESCENT PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG POTENCY; ENDOCYTOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNALIZATION; PROTEIN EXPRESSION; RECEPTOR AFFINITY; SMOOTH MUSCLE CONTRACTILITY; UMBILICAL VEIN;

EID: 84897938628     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00032     Document Type: Article

References (41)

1. 2 receptor endocytosis, recycling, and down-regulation assessed using green fluorescent protein conjugates. J. Pharmacol. Exp. Ther. 297, 19-26.
2. Balti, R., Nedjar-Arroume, N., Yaba Adjé, E., Guillochon, D., and Nasri, M. (2010). Analysis of novel angiotensin-I converting enzyme inhibitory peptides from enzymatic hydrolysates of cuttlefish (Sepia officinalis) muscle proteins. J. Agric. Food Chem. 58, 3840-3846. doi: 10.1021/jf904300q.
3. 2 receptors. Br. J. Pharmacol. 158, 1375-1386. doi: 10.1111/j.1476-5381.2009.00409.x.
4. 8]-bradykinin): pharmacologic profile and effective induction of receptor degradation. J. Pharmacol. Exp. Ther. 323, 534-546. doi: 10.1124/jpet.107.123422.
5. Bawolak, M. T., and Marceau, F. (2007). Does zaltoprofen antagonize the bradykinin receptors? Reg. Pept. 140, 125-130. doi: 10.1016/j.regpep.2006.11.025.
6. 2 receptor stimulated with the amphibian peptide maximakinin: insight into the endosomal inactivation of kinins. Pharmacol. Res. 65, 247-253. doi: 10.1016/j.phrs.2011.11.004.
7. 2 (rhodopsin family) receptor and parathyroid hormone PTH1 (secretin family) receptor. Pharmacol. Res. Perspect. 1:e00004. doi: 10.1002/prp2.4.
8. 2 receptor cycling. Pharmacol. Res. 71, 44-52. doi: 10.1016/j.phrs.2013.02.007.
9. Chercuitte, F., Beaulieu, A. D., Poubelle, P., and Marceau, F. (1987). Carboxypeptidase N (kininase I) activity in blood and synovial fluid from patients with arthritis. Life Sci. 41, 1225-1232. doi: 10.1016/0024-3205(87)90200-1.
10. Choi, K. Y., Swierczewska, M., Lee, S., and Chen, X. (2012). Protease-activated drug development. Therianostics 2, 156-178. doi: 10.7150/thno.4068.
11. Cyr, M., Lepage, Y., Blais, C. Jr., Gervais, N., Cugno, M., and Rouleau, J. L. (2001). Bradykinin and des-Arg9-bradykinin metabolic pathways and kinetics of activation of human plasma. Am. J. Physiol. Heart Circ. Physiol. 281, H275-H283.
12. 2 receptor agonism: a novel therapeutic strategy for myocardial infarction? Am. J. Hypertens. 23, 459. doi: 10.1038/ajh.2010.32.
13. Gainer, J. V., Morrow, J. D., Loveland, A., King, D. J., and Brown, N. J. (1998). Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N. Engl. J. Med. 339, 1285-1292. doi: 10.1056/NEJM199810293391804.
14. Gera, L., Roy, C., Bawolak, M. T., Bouthillier, J., Adam, A., and Marceau, F. (2011). Met-Lys-bradykinin-Ser-Ser, a peptide produced by the neutrophil from kininogen, is metabolically activated by angiotensin converting enzyme in vascular tissue. Pharmacol. Res. 64, 528-534. doi: 10.1016/j.phrs.2011.08.001.
15. Gera, L., Roy, C., Bawolak, M. T., Charest-Morin, X., and Marceau, F. (2012). N-terminal extended conjugates of the agonists and antagonists of both bradykinin receptor subtypes: structure-activity relationship, cell imaging using ligands conjugated with fluorophores and prospect for functionally active cargoes. Peptides 34, 433-446. doi: 10.1016/j.peptides.2012.02.007.
16. 2 receptor. Biol. Chem. 394, 379-383. doi: 10.1515/hsz-2012-0286.
17. Gera, L., Roy, C., and Marceau, F. (2013b). Vasopeptidase-activated latent ligands of the histamine receptor-1. Int. Immunopharmacol. 17, 677-683. doi: 10.1016/j.intimp.2013.08.014.
18. Gobeil, F., Pheng, L. H., Badini, I., Nguyen-Le, X. K., Pizard, A., Rizzi, A., et al. (1996). Receptors for kinins in the human isolated umbilical vein. Br. J. Pharmacol. 118, 289-294. doi: 10.1111/j.1476-5381.1996.tb15401.x.
19. Hornig, B., Kohler, C., and Drexler, H. (1997). Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 95, 1115-1118. doi: 10.1161/01.CIR.95.5.1115.
20. 2 receptor genes on the contractile responses of the human umbilical vein to kinins. J. Pharmacol. Exp. Ther. 294, 45-51.
21. 2 receptor. Hypertension 35, 1319-1325. doi: 10.1161/01.HYP.35.6.1319.
22. Hughes, T. E., Mone, M. D., Russell, M. E., Weldon, S. C., and Villhauer, E. B. (1999). NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry 38, 11597-11603. doi: 10.1021/bi990852f.
23. Izzo, J. L., and Weir, M. R. (2011). Angiotensin-converting enzyme inhibitors. J. Clin. Hypertens. 13, 667-675. doi: 10.1111/j.1751-7176.2011.00508.x.
24. Kahn, R., Hellmark, T., Leeb-Lundberg, L. M., Akbari, N., Todiras, M., Olofsson, T., et al. (2009). Neutrophil-derived proteinase 3 induces kallikrein-independent release of a novel vasoactive kinin. J. Immunol. 182, 7906-7915. doi: 10.4049/jimmunol.0803624.
25. Koumbadinga, G. A., Bawolak, M. T., Marceau, E., Adam, A., Gera, L., and Marceau, F. (2010). A ligand-based approach to investigate the expression and function of angiotensin converting enzyme in intact human umbilical vein endothelial cells. Peptides 31, 1546-1554. doi: 10.1016/j.peptides.2010.04.027.
26. Lambeir, A. M., Durinx, C., Scharpé, S., and De Meester, I. (2003). Dipeptidyl-peptidase IV from the bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 40, 209-294. doi: 10.1080/713609354.
27. Leeb-Lundberg, L. M., Marceau, F., Müller-Esterl, W., Pettibone, D. J., and Zuraw, B. L. (2005). International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 57, 27-77. doi: 10.1124/pr.57.1.2.
28. Manning, D. C., Snyder, S. H., Kachur, J. F., Miller, R. J., and Field, M. (1982). Bradykinin receptor-mediated chloride secretion in intestinal function. Nature 299, 256-259. doi: 10.1038/299256a0.
29. Marceau, F., deBlois, D., Petitclerc, E., Levesque, L., Drapeau, G., Audet, R., et al. (2010). Vascular smooth muscle contractility assays for inflammatory and immunological mediators. Int. Immunopharmacol. 10, 1344-1353. doi: 10.1016/j.intimp.2010.08.016.
30. 2 receptors on the venoconstrictor action of bradykinin. J. Pharmacol. Exp. Ther. 269, 1136-1143.
31. 2 receptor agonist of bradykinin post-acute myocardial infarct. Am. J. Hypertens. 23, 562-568. doi: 10.1038/ajh.2010.20.
32. Michaud, A., Williams, T. A., Chauvet, M. T., and Corvol, P. (1997). Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I. Mol. Pharmacol. 51, 1070-1076.
33. Morissette, G., Couture, J. P., Désormeaux, A., Adam, A., and Marceau, F. (2008). Lack of direct interaction between enalaprilat and the kinin B1 receptors. Peptides 29, 606-612. doi: 10.1016/j.peptides.2007.12.004.
34. Packer, R. J., Krailo, M., Mehta, M., Warren, K., Allen, J., Jakacki, R., et al. (2005). A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas. Cancer 104, 1968-1974. doi: 10.1002/cncr.21403.
35. Plummer, T. H. Jr., and Ryan, T. J. (1981). A potent mercapto bi-product analogue inhibitor for human carboxypeptidase N. Biochem. Biophys. Res. Comm. 98, 448-454. doi: 10.1016/0006-291X(81)90860-3.
36. Potier, L., Waeckel, L., Vincent, M. P., Chollet, C., Gobeil, F., Marre, M., et al. (2013). Selective kinin receptor agonists as cardioprotective agents in myocardial ischemia and diabetes. J. Pharmacol. Exp. Ther. 346, 23-30. doi: 10.1124/jpet.113.203927.
37. Pretorius, M., Rosenbaum, D., Vaughan, D. E., and Brown, N. J. (2003). Angiotensin converting enzyme inhibition increases human vascular-type plasminogen activator release through endogenous bradykinin. Circulation 107, 579-585. doi: 10.1161/01.CIR.0000046268.59922.A4.
38. 1 receptor agonists. Am. J. Physiol. Heart Circ. Physiol. 284, H1959-H1968.
39. Shah, Z., Pineda, C., Kampfrath, T., Maiseyeu, A., Ying, Z., Racoma, I., et al. (2011). Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vasc. Pharmacol. 55, 2-9. doi: 10.1016/j.vph.2011.03.001.
40. 2 receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men. Hypertension 36, 132-136. doi: 10.1161/01.HYP.36.1.132.
41. Taraseviciene-Stewart, L., Scerbavicius, R., Stewart, J. M., Gera, L., Demura, Y., Cool, C., et al. (2005). Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy. Peptides 26, 1292-1300. doi: 10.1016/j.peptides.2005.03.050.